Fertility and Sterility
Volume 93, Issue 4 , Pages 1356-1358 , 1 March 2010

Longitudinal assessment of antimüllerian hormone during pregnancy—relationship with maternal adiposity, insulin, and adiponectin

  • Scott M. Nelson, Ph.D.

      Affiliations

    • Corresponding Author InformationReprint requests: Scott M. Nelson, Ph.D., Reproductive and Maternal Medicine, Faculty of Medicine, University of Glasgow, Glasgow Royal Infirmary, 10 Alexandra Parade, Glasgow, G31 2ER, United Kingdom (FAX: 44-141-552-0873).
    • ,
  • Frances Stewart, M.D.
    • ,
  • Richard Fleming, Ph.D.
    • ,
  • Dilys J. Freeman, Ph.D.

Received 11 June 2009 ,Revised 22 July 2009 ,Accepted 30 July 2009.

References 

  1. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod. 2007;22:2414–2421
  2. Nelson SM, Yates RW, Lyall H, Jamieson M, Traynor I, Gaudoin M, et al. Anti-Mullerian hormone–based approach to controlled ovarian stimulation for assisted conception. Hum Reprod. 2009;24:867–875
  3. La Marca A, Giulini S, Orvieto R, De Leo V, Volpe A. Anti-Mullerian hormone concentrations in maternal serum during pregnancy. Hum Reprod. 2005;20:1569–1572
  4. Lutterodt M, Byskov AG, Skouby SO, Tabor A. Yding Andersen C. Anti-Mullerian hormone in pregnant women in relation to other hormones, fetal sex and in circulation of second trimester fetuses. Reprod Biomed Online. 2009;18:694–699
  5. Pigny P, Merlen E, Robert Y, Cortet-Rudelli C, Decanter C, Jonard S, et al. Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957–5962
  6. Piltonen T, Morin-Papunen L, Koivunen R, Perheentupa A, Ruokonen A, Tapanainen JS. Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod. 2005;20:1820–1826
  7. Freeman EW, Gracia CR, Sammel MD, Lin H, Lim LC, Strauss JF. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil Steril. 2007;87:101–106
  8. Chen MJ, Yang WS, Chen CL, Wu MY, Yang YS, Ho HN. The relationship between anti-Mullerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod. 2008;23:952–957
  9. Bayrak A, Terbell H, Urwitz-Lane R, Mor E, Stanczyk FZ, Paulson RJ. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Fertil Steril. 2007;87:870–875
  10. Harborne LR, Sattar N, Norman JE, Fleming R. Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab. 2005;90:4593–4598
  11. Drolet R, Belanger C, Fortier M, Huot C, Mailloux J, Legare D, et al. Fat depot–specific impact of visceral obesity on adipocyte adiponectin release in women. Obesity (Silver Spring). 2009;17:424–430
  12. Chabrolle C, Tosca L, Dupont J. Regulation of adiponectin and its receptors in rat ovary by human chorionic gonadotrophin treatment and potential involvement of adiponectin in granulosa cell steroidogenesis. Reproduction. 2007;133:719–731

 S.M.N. has nothing to disclose. F.S. has nothing to disclose. R.F. has nothing to disclose. D.J.F. has nothing to disclose.

PII: S0015-0282(09)03473-6

doi: 10.1016/j.fertnstert.2009.07.1676

Fertility and Sterility
Volume 93, Issue 4 , Pages 1356-1358 , 1 March 2010

Article Tools